Atopia Therapeutics is developing ATP-R13, a recombinant protein derived from *Helicobacter pylori*, to modulate the immune response and reduce inflammation in patients with asthma, eczema, and food allergies. This first-in-class therapy aims to address the rising prevalence of allergic diseases affecting billions globally by re-establishing immune tolerance and alleviating symptoms.
Funding
Funding not disclosed
Founders
Product
Problem
The rising global prevalence of asthma, eczema, food allergies, and other allergic diseases represents a significant unmet medical need, affecting billions of individuals. Current treatments often fail to address the underlying immune system imbalances that drive these conditions, leading to inadequately controlled symptoms, especially in children. The decreasing incidence of *Helicobacter pylori* in developed countries correlates with an increase in allergic disorders, suggesting a link between the microbiome and immune tolerance.
Solution
Atopia Therapeutics is developing ATP-R13, a first-in-class, disease-modifying therapy based on a recombinant protein derived from *Helicobacter pylori*. This patented and optimized immunomodulatory protein is designed to be administered orally, working independently of the specific antigen to re-equilibrate the immune system and reduce inflammation. By mimicking the protective effects of *H. pylori* on the immune system, ATP-R13 aims to restore immune tolerance and alleviate symptoms associated with a range of allergic diseases, potentially addressing multiple indications of the atopic march, including atopic dermatitis, allergic rhinitis, food allergy, and IBD. The company has completed lead optimization and is initiating IND-enabling activities.
Target Audience
The primary target audience includes individuals suffering from asthma, eczema, food allergies, and other allergic diseases, as well as pharmaceutical companies seeking novel therapies for immune-related disorders.
Features
- Recombinant protein based on a molecule from *Helicobacter pylori*
- Oral administration for convenient and systemic immune modulation
- Antigen-independent mechanism of action, targeting the underlying immune imbalance
- Demonstrated tolerability and lack of toxicity in preclinical studies
- Potential application across multiple allergic indications, including asthma, eczema, allergic rhinitis, and food allergies
- Exclusive worldwide license from the University of Zurich
- Composition of Matter patent filed in 2024 on the optimized clinical candidate